Medical Imaging Markets Volume IV Contrast Agents

Countries covered: Global

Contrast agents and radiopharmaceuticals have revolutionized in vivo imaging. Technical developments in contrast media and imaging techniques is combining with the trends toward both the functional and molecular understanding of disease to create a rapidly growing marketplace in these agents.

The introduction and now brisk ongoing development of contrast media for traditional radiography, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron-emission tomography (PET), and single-photon emission computed tomography (SPECT), are now allowing for the expansion of diagnostic capabilities of these modalities. Dozens of agents are being developed with the hopes of opening up new applications for existing modalities. While some agents will compete with existing agents while others aim to break new ground and provide a diagnostic assessment that is not currently available today.

This comprehensive study of the world market for contrast agents builds on the previous modality-focused reports of Kalorama’s Medical Imaging Markets series and includes:

World and regional revenue forecasts for contrast agents and radiopharmaceuticals by modality through 2010.

Market share of the major contrast agent supplers

Procedure volumes by modality and region

Estimates of the portion of procedures in each modality using contrast enhancement

Contrast-enhancement products in development

The report also discusses technical developments and emerging application trends such as therapeutic monitoring, whole body screening, and guided therapeutic interventions, and how contrast agents are helping to expand imaging’s role in basic research and drug discovery/development. Specific advances in contrast agent-enabled diagnostics for mammography, Alzheimer’s, and other indications are also reviewed.

The report concludes with profiles of top suppliers and developers including:

Acusphere Inc.

Advanced Magnetics Inc.

ART Advanced Research Technologies Inc.

Bristol-Myers Squibb

Boston Life Sciences

Bracco SpA

Cell Point

Cytogen Corp.

Daiichi Pharmaceutical Co. Ltd.

Dendritic NanoTechnologies Inc.

Dowpharma

Draximage

Epix Pharmaceuticals Inc.

E-Z-EM Inc.

GE Healthcare

Guerbet Group

Hovione FarmaCiencia SA

Imcor Pharmaceutical Co.

Immunomedics Inc.

King Pharmaceuticals Inc.

Luna nanoWorks

Macrocyclics

Mallinckrodt

Palatin Technologies Inc.

Pharmacyclics

Point Biomedical Corp.

Schering AG

February 1, 2007

125 Pages - Pub ID: KLI1340230 Format PDF
Table of Contents
Price: $2,995.00 / GBP1,497.50